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Abstract
Background: Diaphanous-related formins govern actin-based processes involved in many cellular functions, such as 
cell movement and invasion. Possible connections to developmental processes and cellular changes associated with 
malignant phenotype make them interesting study targets. In spite of this, very little is known of the tissue distribution 
and cellular location of any mammalian formin. Here we have carried out a comprehensive analysis of the formin family 
member formin -like 2 (FMNL2) in human tissues.
Results: An FMNL2 antibody was raised and characterized. The affinity-purified FMNL2 antibody was validated by 
Western blotting, Northern blotting, a peptide competition assay and siRNA experiments. Bioinformatics-based mRNA 
profiling indicated that FMNL2 is widely expressed in human tissues. The highest mRNA levels were seen in central and 
peripheral nervous systems. Immunohistochemical analysis of 26 different human tissues showed that FMNL2 is widely 
expressed, in agreement with the mRNA profile. The widest expression was detected in the central nervous system, 
since both neurons and glial cells expressed FMNL2. Strong expression was also seen in many epithelia. However, the 
expression in different cell types was not ubiquitous. Many mesenchymal cell types showed weak immunoreactivity 
and cells lacking expression were seen in many tissues. The subcellular location of FMNL2 was cytoplasmic, and in 
some tissues a strong perinuclear dot was detected. In cultured cells FMNL2 showed mostly a cytoplasmic localization 
with perinuclear accumulation consistent with the Golgi apparatus. Furthermore, FMNL2 co-localized with F-actin to 
the tips of cellular protrusions in WM164 human melanoma cells. This finding is in line with FMNL2's proposed function 
in the formation of actin filaments in cellular protrusions, during amoeboid cellular migration.
Conclusion: FMNL2 is expressed in multiple human tissues, not only in the central nervous system. The expression is 
especially strong in gastrointestinal and mammary epithelia, lymphatic tissues, placenta, and in the reproductive tract. 
In cultured melanoma cells, FMNL2 co-localizes with F-actin dots at the tips of cellular protrusions.
Background
The formin family consists of large multidomain proteins
that control cytoskeletal organization [1]. Formins are
conserved in all eukaryotes, where they govern complex
cellular processes such as cell shape and motility, migra-
tion and cytokinesis. The human genome contains 15
formin genes that are subdivided in Diaphanous-related
formins (DRFs) and non-DRFs. The protein family is
defined by the formin homology 2 domain (FH2), capable
of polymerization straight actin filaments. FH2 attaches
to the actin filament during elongation, protecting it from
capping proteins. Almost all formins contain a proline-
rich formin homology 1 domain (FH1) N-terminal to
FH2. FH1 enhances actin nucleation by recruiting profi-
lin-bound actin monomers for FH2 actions.
Formin-like 2 (FMNL2), a member of the DRFs, con-
tains a GTPase-binding domain and autoregulatory
domains, and is proposed to function as a downstream
effector of Rho family guanosine triphosphatases
(GTPases) [2]. Rho GTPases influence cell morphology
by activating effectors in different cellular compartments.
As most formins, the mouse FMNL2 orthologue is
known to polymerize actin filaments [3].
Furthermore, DRFs are tied to transcriptional regula-
tion, mediating the activation of serum response factor
(SRF). SRF activation in turn, leads to transcription of
several cytoskeleton-associated genes [4]. Recently, a
microdeletion including the FMNL2 gene was associated
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with precocious puberty, short stature and severe mental
retardation [5].
As actin regulation is a fundamental process, inherited
or acquired defects in this complex activity can result in
different diseases. These include developmental disor-
ders, muscle disorders, various neoplasias, immune defi-
ciencies, diseases of the nervous system and kidney
diseases. As key regulators of cytoskeletal dynamics,
formins are interesting not only from a biological but also
from a disease perspective. Despite intensive studies, the
distinct functions of different formins remain unresolved.
FMNL2 mRNA is expressed in many normal tissues and
cancers [6]. Surprisingly, the presence of FMNL2 protein
has not systematically been studied by immunohis-
tochemistry in any species, possibly due to the lack of
antibodies suitable for such analysis. The aim of this
study was to determine the expression profile of FMNL2
in normal human tissues, using an antibody designed for
immunohistochemistry. The expression pattern can be
used as a reference in further analyses of FMNL2 biologi-
cal functions and disease associations.
Methods
mRNA expression analysis
The GeneSapiens database was utilized to study the
FMNL2 mRNA expression across all human normal tis-
sues [7]. All the samples included in this database have
been analyzed on the Affymetrix platform and due to
unique normalization and data quality verifications, gene
expression profiles collected from different studies can be
combined to generate an overview of the expression pro-
file in human tissues.
Tissue samples and immunohistochemistry
Tissue samples were collected for this study prospectively
from surgical specimens sent to the Department of
Pathology at the Turku University Central Hospital for
diagnostic purposes. Informed consent was asked before
surgery. The procedure was approved by the Hospital
District Ethics Committee. Within one hour from surgi-
cal removal, macroscopically normal tissue areas were
sampled. Central nervous tissue specimens were an
exception, as autopsy material was collected. Tissues
were fixed in formalin, dehydrated, paraffin-embedded
and sectioned.
Immunostaining was performed using the streptavid-
ine-peroxidase method, using a LabVision autostainer
device. For antigen retrieval, the slides were treated with
citrate buffer (pH 6.0). Endogenous peroxidase was
blocked with 3% H2O2. After 30 min incubation in nor-
mal nonimmune serum at 37°C, the sections were incu-
bated 60 min at 4°C in affinity-purified rabbit FMNL2
antibody (Atlas Antibodies, Stockholm, Sweden; 1:75
dilution). After washing with PBS, the sections were
treated with biotin-conjugated secondary antibody, fol-
lowed by streptavidine-peroxidase. Diaminobenzidine
was used as a chromogene. Individual tissues and cell
types were evaluated by scoring the staining intensity by
grading from 0 (no staining) to + + + (strong staining).
Northern hybridization of human cell lines
Total RNA was isolated from the cell line samples using
Trizol Reagent (Invitrogen, Carlsbad, CA), according to
manufacturer instructions. The concentration of RNA
was determined spectrophotometrically and the quality
was analyzed by agarose gel electrophoresis and ethidium
bromide staining by evaluating the integrity of 28S and
18S ribosomal RNAs. Northern blotting, hybridization
and the detection of the hybridized probe was performed
according to DIG Application Manual for Filter Hybrid-
ization (Roche Applied Science, Mannheim, Germany)
with some modifications. Briefly, 1.0 μg of total RNA was
size-fractionated on a denaturing 1.3% agarose/formalde-
hyde gel and stained with ethidium bromide. RNA was
blotted to a positively charged nylon membrane (Roche
Applied Science) by capillary transfer. RNA was treated
with 50 mM NaOH before transfer. The membrane was
UV-crosslinked (UV Stratalinker™ 2400, Stratagene, La
Jolla, CA) and equal quantity of transfered RNA samples
was checked with ethidium bromide. After prehybridiza-
tion for an hour in high SDS hybridization buffer [50%
deionized formamide, 5 × SSC, 50 mM sodium phos-
phate pH 7, 7% SDS, 0.1% N-lauroylsarcosine, 2% Block-
ing Reagent (Roche Applied Science)] at 50°C, the
membrane was hybridized in the same solution overnight
at 50°C with a denaturated DIG-11-UTP labelled human
FMNL2 RNA probe (DIG RNA Labelling Kit SP6/T7,
Roche Applied Science). The sequence of the probe
matched the antibody epitope (NCBI RNA RefSeq clone
GenBank: NM_052905.3, bases 1544 - 1871). The final
washing conditions were 0.5 × SSC, 0.1% SDS at 65°C for
two times 15 min. The amount of hybridized probe was
visualized with alkaline phosphatase labelled Anti-Digox-
igenin Fab Fragments (Roche Applied Science) and
chemiluminescent detection using CDP-Star  substrate
(Roche Applied Science).
Western blotting of human cell lines
Cells from seven different human lines (MCF-7 = breast
carcinoma, HaCaT = keratinocyte, A431 = squamous cell
carcinoma, MKN-1 = gastric carcinoma, WM164 = mela-
noma, Jurkat = T-cell lymphoma, K562 = erythroleuke-
mia) were harvested and lysed in ELB buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA), 1% Non-
idet P-40 or in RIPA buffer supplemented with protease
inhibitors. Samples were normalized for protein concen-
tration and equal amounts of material in Laemmli sample
buffer were subjected to SDS-PAGE, transferred to nitro-Gardberg et al. BMC Cell Biology 2010, 11:55
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cellulose filters and immunoblotted with FMNL2 anti-
body (1:2000, 60 min) in BSA/TBS/Tween 0,1%, followed
by secondary antibody [HRP-conjugated swine anti-rab-
bit (Dako, Glostrup, Denmark)]. Bound proteins were
detected by enhanced chemiluminescence. To verify the
specificity of the FMNL2 antibody, its reactivity was
blocked by 1 hour preincubation with a 100-fold molar
excess of the GST-FMNL2 - fusion protein (residues 393-
516), or as a control, with GST. The α-tubulin antibody,
used as a control for protein loading, was from Invitro-
gen.
FMNL2 small interfering (si) RNA
FMNL2 expression was silenced in MKN-1 and WM164
cells using SMARTpool siRNA (Dharmacon Research,
Boulder, CA). Non-targeting Pool siRNA (Dharmacon)
was used as a control. Cells were transfected with Dhar-
mafect 1 (Dharmacon) according to manufacturer's
instructions. FMNL2 levels were examined in cell lysates
72 hours after transfection by immunoblotting.
Immunocytochemical analysis
WM164, A431 and MKN-1 cells were cultured on cover-
slips and fixed with 4% paraformaldehyde for 15 min. The
cells were permeabilized in cold acetone for 5 min. After
15 min in 1% BSA in PBS, the cells were incubated for one
hour with the FMNL2 antibody (1:150), followed by a
secondary antibody, Alexa 568-conjugated goat anti-rab-
bit (Molecular Probes, Eugene, OR). F-actin was visual-
ized with Alexa 488-conjugated phalloidin (Molecular
Probes). The mounting media contained DAPI for stain-
ing nuclei (Vector Laboratories, Burlingame, CA). In con-
trol slides the primary antibody was replaced with 1%
BSA in PBS. The cells were imaged with a Zeiss LSM 510
Meta confocal microscope (Carl Zeiss, 63 × Plan Apo-
chromat objective, Göttingen, Germany). Image J 1.42q
(NIH, USA) software was used in picture analyses.
Results
Antibody validation
The FMNL2 rabbit anti-human polyclonal monospecific
antibody was produced by the Swedish Human Proteome
Resource (HPR), in a project with emphasis on generating
antibodies for immunohistochemistry [8]. An epitope
specific for FMNL2 (Uniprot Q96PY5, amino-acids 393-
516) was chosen for recombinant protein production of
Protein Epitope Signature Tags (PrESTs) and for immuni-
zation. Rabbit polyclonal antibodies were affinity purified
and initially validated by ELISA-based PrEST-array of
antibody specificity. In this assay, the antibody was highly
specific.
To further validate the FMNL2 antibody, Western and
Northern blot analyses were carried out on several cell
lines. Based on sequence information, the predicted
molecular mass of FMNL2 is 124 kDa. The FMNL2 anti-
body detected a single band slightly higher than expected
size (140 kDa) in the human cell lines MCF-7, HaCat,
A431, MKN-1 and WM164. No band was detected in Jur-
kat and K562 cells (Figure 1a). The reactivity of the anti-
body was confirmed by a peptide competition assay.
Preincubation of the antibody with GST-FMNL2 fusion
protein resulted in loss of the 140 kDa band in all three
tested cell lines, A431, MKN-1 and WM164, whereas
preincubation with GST did not alter the reactivity (Fig-
ure 1b).
As a further test, WM164 and MKN-1 cells were trans-
f e c t e d  w i t h  F M N L 2 - s p e c i f i c  s i R N A  o r  w i t h  c o n t r o l
siRNA, and lysates were blotted with the FMNL2 anti-
body. FMNL2 knockdown resulted in markedly reduced
or undetectable antibody reactivity, whereas control
siRNA had no effect on antibody reactivity (Figure 1c).
The FMNL2 transcript in the cultured cells was ana-
lyzed by Northern blotting. The analysis revealed a major
5.6 kb transcript in all four cell lines, in which FMNL2
was detected by Western blotting. In A431, MKN-1 and
WM164 cells an additional weaker and smaller band was
seen. In Jurkat cells, no transcript was detected (Figure
1d).
FMNL2 mRNA expression in human tissues
To gain an overall picture of FMNL2 mRNA expression in
various human tissues, gene expression data from Genes-
Sapiens database was utilized. FMNL2 mRNA expression
profile across human tissues is presented in Figure 2.
Overall, FMNL2 mRNA was widely expressed. The high-
est mRNA expression was seen in central and peripheral
nervous systems. Relatively high expression was detected
in ovary, placenta, colorectal tissues, respiratory and
endocrine systems, and salivary gland. The lowest expres-
sion of FMNL2 was seen in bone marrow, testis, liver/bil-
iary system, heart and pancreas [9].
Immunohistochemical analysis of FMNL2 in human tissues
Immunohistochemical analysis of 26 different human tis-
sues was performed, and the results are summarized in
Table 1. Examples of the staining results and cellular dis-
tribution of FMNL2 are shown in Figure 3. As an overall
impression, most tissues and cell types expressed FMNL2
although the staining intensity varied. The subcellular
location of FMNL2 was cytoplasmic and the distribution
appeared to be uniform.
Central nervous system
In the brain, both nerve cells and glial cells expressed
FMNL2 widely and abundantly (Figure 3a). In samples
taken from 41 different areas of the brain, moderate to
strong staining was seen in neurons, oligodendroglial
cells and astrocytes alike.Gardberg et al. BMC Cell Biology 2010, 11:55
http://www.biomedcentral.com/1471-2121/11/55
Page 4 of 10
Respiratory system
In the lung, expression was strong in alveolar mac-
rophages, but weak in alveolar epithelium (Figure 3b).
The respiratory epithelium in bronchi expressed FMNL2
strongly.
Gastrointestinal system
FMNL2 expression was strong in epithelia of the stom-
ach, duodenum, jejunum, and colon. Moderate expres-
sion was seen in the glandular cells of parotid gland.
In the esophagus, pancreas and liver, staining was weak
indicating low expression. However, the pancreatic neu-
roendocrine cells of Langerhans islets showed intense
immunoreactivity (Figure 3c). While most cell types had
uniform cytosplasmic staining, the secretory epithelia
stained granularly and enterocytes had a particularly
strong apical perinuclear dot. Ganglion cells, represent-
ing the peripheral nervous system, expressed FMNL2
abundantly.
Endocrine organs
Samples from thyroid gland, parathyroid gland and adre-
nal gland were studied. In all three locations, FMNL2 was
strongly expressed. Expression was equally strong both in
the cortex and medulla of the adrenal gland. Follicular
epithelial cells of the thyroid gland and parathyroid chief
cells also expressed FMNL2 strongly. Parathyroid oxyphil
cells, in contrast, stained weakly.
Figure 1 Validation of FMNL2 antibody. a) Western blot analysis of 
FMNL2 protein in seven human cell lines. A single band, of approxi-
mately 140 kDa, is detected in five cell lines. b) Western blot analysis 
with FMNL2 antibody competed either with GST-FMNL2 fusion pro-
tein or GST. Competition with GST-FMNL2 but not GST results in disap-
pearance of the 140 kDa FMNL2 band. c) Western blot analysis of 
WM164 and MKN-1 cells transfected with FMNL2-specific siRNA, non-
targeting (nt) siRNA or without siRNA (control). FMNL2 siRNA markedly 
reduces FMNL2 reactivity in both cell types. The α-tubulin blot con-
firms equal protein loading. d) Northern blot analysis of FMNL2 mRNA 
in six human cell lines. A 5.6 kb band is seen in all five cell lines, in which 
the Western blot analysis detects the protein band.
Figure 2 FMNL2 mRNA expression profile in normal human tis-
sues. The normalized expression values (y-axis) of FMNL2 across nor-
mal tissues (x-axis) are presented as box-plots. The box extends from 
the first to the third quartile of the data and the median is indicated 
with green. The whiskers extend to the extreme values unless there are 
outliers. The data observations that lie more than 1.5 * interquartile 
range (IQR) lower than the first quartile, or 1.5 * IQR higher than the 
third quartile are considered as outliers and indicated separately. High-
est expression levels are seen in central and peripheral nervous sys-
tems.Gardberg et al. BMC Cell Biology 2010, 11:55
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Table 1: Expression of FMNL2 in various tissues and cell types
Tissue Cell type Staining* Comments
Adrenal gland Cortical cells +++ Partly granular
Medullary cells +++ Partly granular
Bone marrow Erythroid cells 0
Myeloid cells ++
Megakaryocytes +++
Breast Ductal epithelium +++
Lobular epithelium +++
Myoepithelium ++
Brain Neurons +++
Glial cells +++
Colon Epithelium +++
Duodenum Surface epithelium +++ Perinuclear apical dot
Brunner glands ++
Stromal cells +
Esophagus Squamous epithelium + Basal layer ++, surface layer 0
Kidney Podocytes +++
Mesangial cells 0
Tubular epithelium ++ Variable
Liver Hepatocytes +
Biliary duct epithelium +
Lung Alveolar epithelium +
Alveolar macrophages +++
Lymph node Follicular cells +++Gardberg et al. BMC Cell Biology 2010, 11:55
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Paracortical cells +++
Ovary Granulosa cells +++
Stromal cells ++
Pancreas Exocrine epithelium + Partly granular
Ductal epithelium +
Endocrine cells +++
Parathyroid gland Chief cells +++
Oxyphil cells +
Parotid gland Acinar cells ++ Partly granular
Adipocytes 0
Placenta Trophoblast +++
Stromal cells +
Endothelium 0
Prostate Epithelium ++ Perinuclear apical dot
Smooth mucle cells +
Peripheral nerve cells ++
Skin Keratinocytes + Basal layer ++, surface layer 0
Small intestine Enterocytes +++
Spleen White pulp cells +++
Red pulp cells +++
Stomach Glandular cells +++ Partly granular apically Surface epithelium weak
Stromal cells +
Striated muscle Myocytes +
Testis Spermatocytes +++
Sertoli cells +++
Table 1: Expression of FMNL2 in various tissues and cell types (Continued)Gardberg et al. BMC Cell Biology 2010, 11:55
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Urinary system
Samples from kidney and urinary bladder were analyzed
as examples of the urinary system. FMNL2 was present in
both tissues. In the kidney, mesangial cells did not
express FMNL2. Podocytes, on the other hand, expressed
FMNL2 abundantly (Figure 3d). Tubular epithelial cells
varied in intensity, most tubules stained moderately. In
the urinary bladder, urothelial cells expressed FMNL2
moderately. Intensity was weaker in umbrella cells than in
basal cells.
Female reproductive system
In the fertile ovary, FMNL2 was expressed in several cell
types. Granulosa cells surrounding the maturing oocyte
expressed FMNL2 strongly. The oocyte itself, as well as
stromal cells, expressed FMNL2 moderately. In the
uterus, myometrial smooth muscle cells expressed
FMNL2 moderately. A perinuclear particularly strongly
staining dot was noted. Secretory phase endometrial
glands expressed FMNL2 strongly, stromal cells weakly
(Figure 3e). In the non-lactating breast, FMNL2 was
strongly expressed in both ductal and lobular epithelium.
Myoepithelial cells stained moderately. In the full term
placenta, both syncytiotrophoblast and trophoblast cells
expressed FMNL2 strongly, whereas the staining of
stromal cells was weak (Figure 3f).
Male reproductive system
FMNL2 immunoreactivity was detected both in testis and
prostate. In testis, strong expression was seen both in
spermatocytes and Sertoli cells. Leydig cells, in contrast,
expressed FMNL2 weakly. In the prostate, epithelial cells
expressed FMNL2 moderately, with an especially strong
perinuclear apical dot (Figure 3g). Smooth muscle cells
stained weakly. Moderate staining was seen in prostatic
peripheral nerves.
Haematopoietic system
Samples from lymph node, spleen and bone marrow rep-
resented the hematopoietic system. In all these tissues,
FMNL2 was detected. In both the lymph node and
spleen, FMNL2 was widely and strongly expressed. In the
bone marrow, erythroid cells did not express FMNL2.
Megakaryocytes, on the other hand, expressed FMNL2
abundantly. Myeloid cells stained moderately (Figure 3h).
Skin
FMNL2 was present in epidermal keratinocytes and adn-
exal structures. In the epidermis, basal layers stained
moderately. Expression gradually weakened toward the
surface. Superficial cells did not express FMNL2.
Vasculature
In vessel walls, FMNL2 expression was weak or negative
in endothelial cells. In muscular arteries, also smooth
muscle cells stained weakly.
Skeletal muscle
In striated muscle, weak FMNL2 expression was
detected. FMNL2 was uniformly distributed, without a
striated pattern.
Subcellular distribution of FMNL2 in WM164, A431 and 
MKN-1 cells
To study the subcellular location of FMNL2 in detail,
WM164, A431 and MKN-1 cells were stained with
FMNL2 antibody, phalloidin and DAPI. Confocal micro-
scopic analysis revealed a primarily cytoplasmic distribu-
tion of FMNL2 in all three cell types. FMNL2 often
showed perinuclear accumulation in WM164 and A431
cells, consistent with the Golgi apparatus (Figure 4,
arrowheads). A similar staining pattern was occasionally
observed in MKN-1 cells (not shown).
In MKN-1 and A431 cells, FMNL2 staining did not co-
localize with F-actin, visualized by phalloidin staining.
Instead, in WM164 cells a partial overlap was seen. In
contrast to the other cell types WM164 cells contained
protrusions with long actin filaments. Dots containing
both FMNL2 and F-actin were observed at the tips of
these protrusions in most of the analyzed cells (Figure 4,
arrows).
Leydig cells +
Thyroid gland Epithelium +++
Urinary bladder Urothelial cells ++ Weak in umbrella cells
Uterus Smooth muscle cells ++ Perinuclear dot
Secretory epithelium +++
Secretory stromal cells +
*0 = no staining, + = weak staining, + + = moderate staining, + + + = strong staining
Table 1: Expression of FMNL2 in various tissues and cell types (Continued)Gardberg et al. BMC Cell Biology 2010, 11:55
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Discussion
The expression of different formin proteins in human tis-
sues has not been systematically investigated. As the pro-
tein family has 15 members, the proteins are expected to
possess individual and different functions and expression
patterns, reflecting the demands for cytoskeletal regula-
tion in various cell types. Here, we set out to investigate
how widely FMNL2 is expressed by using immunohis-
t o c h e m i s t ry .  A n  a n t i b o d y  w a s  r a i s e d  f o r  t h i s  p u r p o s e .
After validation by Western and Northern blotting, as
well as a peptide competition and siRNA experiments, we
conclude that this antibody is specific and suitable for
immunohistochemistry.
FMNL2 mRNA has been reported to be expressed in
many normal tissues [6]. Using a large set of information
on FMNL2 transcripts, we confirmed that FMNL2
mRNA indeed can be detected in virtually all tissues [7].
Highest expression was seen in the central nervous sys-
tem, followed by the peripheral nervous system and sev-
eral epithelial tissues. A consistent result was achieved by
immunohistochemical analysis of 26 tissues. In the cen-
tral nervous system, expression was wide, as strong
expression was seen both in neurons and supporting glial
cells. Strong expression was, however, not exclusive for
nervous tissues. Moderate or strong expression was seen
in most epithelia and lymphatic tissues. Especially gas-
tric, intestinal, mammary and endocrine epithelia
expressed FMNL2 strongly. Connective tissue compo-
nents including fibroblasts, endothelium and adipose
cells expressed little or no FMNL2. It will be interesting
to study whether FMNL2 expression changes in invasive
cancer, when epithelial cells lose their polarity and cell-
to-cell contacts.
In the hematopoietic system, lymphocytes, myeloid
precursors and macrophages displayed moderate to
strong FMNL2 expression. Erythroid precursors, as well
as mature red blood cells were negative. Consistent with
Figure 3 Immunohistochemical analysis of FMNL2 in human tis-
sues. a) In the hippocampus, both neurons (N) and glial cells (G) ex-
press FMNL2 strongly. b) In the lung, FMNL2 expression is strong in 
macrophages (M), but weak in alveolar epithelium. c) The exocrine 
pancreas stains weakly and granularly for FMNL2. The neuroendocrine 
cells in the Langerhans islets (L) stain strongly. d) In the kidney, glom-
erular mesangial cells (arrow) do not expess FMNL2. In contrast, podo-
cytes (P) and part of the tubules express FMNL2. e) In secretory 
endometrium, FMNL2 expression is strong in glandular epithelium (G), 
but weak in the stromal cells. f) In the placenta, trophoblasts (arrow) ex-
press FMNL2 strongly. g) In the prostate, epithelial cells stain intensely, 
with an apical perinuclear dot (asterisk). h) In the bone marrow, the 
strongest FMNL2 expression is seen in megakaryocytes (arrow). (a - h 
original magnification × 200)
Figure 4 Confocal microscopic analysis of FMNL2 in WM164 mel-
anoma cells and A431 squamous cell carcinoma cells. FMNL2 (left, 
red) was visualized with antibody, F-actin (middle, green) with phalloi-
din, the nucleus with DAPI (blue) and the cells analyzed with a confocal 
microsope. Top row: In WM164 cells, FMNL2 is located both diffusely in 
the cytoplasm and perinuclearly (blue) consistent with the location of 
the Golgi apparatus (arrowhead). WM164 cells have prominent protru-
sions with long actin filaments. At the tips of these protrusions, FMNL2 
and F-actin are co-localized (arrows). Bottom row: A431 cells lack pro-
trusions. FMNL2 is seen in the cytoplasm, faintly concentrated to the 
perinuclear location (arrowhead). No co-localization with F-actin is ev-
ident. Bar = 20 μm.Gardberg et al. BMC Cell Biology 2010, 11:55
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this, no FMNL2 was detected by Western blotting in the
K562 erythroleukemia cells. Such cell-type specific
expression in cells differentiating from a common precur-
sor may have clinical implications. Another DRF, Diapha-
nous 1 (mDia1), has been linked to bone marrow disease.
mDia1 knockout mice develop age-dependent myelopro-
liferative defects mimicking human myeloproliferative
and myelodysplastic syndromes [10]. FMNL2 could also
be involved in diseases with defects in myelopoiesis.
However, the phenotype of an FMNL2 knockout mouse
has not been described.
One of the epithelia expressing FMNL2 was colon. The
expression was relatively high both as analyzed by mRNA
signal and immunohistochemistry. Our findings are dis-
tinct from the results reported in a study linking
increased FMNL2 expression to metastatic activity in col-
orectal canc er . In t ha t st udy , normal color ectal epithe-
lium was reported to be devoid of FMNL2 or express it
only weakly [11]. The difference may be due to several
causes. The previously reported antibody may have a
lower sensitivity than ours, resulting in positive immuno-
reactivity only in tissues with exceptionally high FMNL2
expression. Also, the antibodies may have different iso-
form-specifity. The antibody used for the colorectal can-
cer metastasis study was directed toward an antigen in
FMNL2 isoform 1 that shares 91% identity with FMNL2
isoform 2. It is possible that the antibody has weaker or
no affinity to FMNL2 isoform 2. In contrast, the antibody
used in our study was raised towards a sequence common
to both isoforms. The colorectal metastasis study illus-
trated the relative change of FMNL2 expression in nor-
mal colon and colorectal adenocarcinoma, especially
metastatic disease. At this point, we conclude that nor-
mal colorectal mucosa does express FMNL2, but do not
compare the level of expression to cancer. Thus, our
results do not necessarily contradict the conclusions
made. Our preliminary transcription analysis indicates
that FMNL2 expression is up-regulated in several forms
of cancer, and future studies will be directed to find the
ones where this difference has biological and medical rel-
evance.
Uncontrolled proliferation, combined with invasive and
metastatic potential, is a hallmark of malignancy. Rho
GTPases have been shown to mediate cytoskeletal
changes essential for malignant cell behavior in vitro, and
evidence of in vivo relevance is mounting. Rho GTPases
activate effector molecules in different cellular locations.
Effectors, in turn, mediate cytoskeletal changes [12].
Identifying Rho GTPase effectors is crucial for under-
standing actin remodeling in normal and malignant cells.
FMNL2 contains a GTPase binding domain. Recently,
FMNL2 was identified as a specific RhoC effector [13]. In
the same study, RhoC and FMNL2 were, by using RNA
interference, found to be essential for the invasive motil-
ity of rounded human melanoma cells. FMNL2 silencing
did not affect the invasive capacity of breast carcinoma
cells or fibrosarcoma cells, which display a more mesen-
chymal elongated morphology. In our study, confocal
microscopy of WM164 melanoma cells revealed a co-
localization of F-actin and FMNL2 at the tips of cell pro-
trusions. A431 squamous cell carcinoma cells and MKN-
1 gastric carcinoma cells had a different, unspiked mor-
phology and in these cells FMNL2 and F-actin were not
co-localized. These results are in agreement with the
finding that FMNL2 has cell-specific functions and that it
has a special role in protrusions of invading melanoma
cells.
As Rho GTPase expression levels change in malignan-
cies, changes in effectors are to be expected. Without
doubt, several other formins will in the near future be
identified as effectors specific Rho GTPases. Understand-
ing the cascades behind malignant cell behavior in differ-
ent malignancies can ultimately offer targets for novel
therapies.
Conclusions
With a novel FMNL2 antibody, we show that immunohis-
tochemistry is a useful method of investigating FMNL2
expression in human tissues. In healthy tissues, FMNL2 is
widely expressed. Highest expression is in the central ner-
vous system. In melanoma cells, FMNL2 shows a distinct
co-localization with actin dots in cellular protrusions.
Studies on FMNL2 in cancer tissues are warranted.
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